-
Mashup Score: 47Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3 - 10 month(s) ago
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline. PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continua
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3 - 10 month(s) ago
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline. PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This ASCO living guideline
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert HOT OFF THE PRESS @ASCO Living #Guideline Update by great experts @JCO_ASCO on: “Therapy for Stage IV Non-Small-Cell #LungCancer WITHOUT Driver Alterations” #NSCLC #LCSM 👇🏼 https://t.co/WYnZ8hHbPY https://t.co/KuztrqFsoq
-
-
Mashup Score: 25Qualtrics Survey | Qualtrics Experience Management - 10 month(s) ago
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
Source: iaslc.co1.qualtrics.comCategories: General Medicine News, Hem/OncsTweet-
🔥🚨The International Association for the Study of Lung Cancer @IASLC needs your help completing a SHORT survey on a very important topic: “#Biomarker Testing in #LungCancer” Survey will help improve #Care for #Patients. Please share. Survey link👇🏼 https://t.co/X4zxmX3dSL https://t.co/xZ2pPJZRi8
-
-
Mashup Score: 25Qualtrics Survey | Qualtrics Experience Management - 10 month(s) ago
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
Source: iaslc.co1.qualtrics.comCategories: General Medicine News, Hem/OncsTweet-
🔥🚨The International Association for the Study of Lung Cancer @IASLC needs your help completing a SHORT survey on a very important topic: “#Biomarker Testing in #LungCancer” Survey will help improve #Care for #Patients. Please share. Survey link👇🏼 https://t.co/X4zxmX3dSL https://t.co/xZ2pPJZRi8
-
-
Mashup Score: 103Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - 10 month(s) ago
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favourable trend for Tagrisso, although data were not mature
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🚨Hot off the press. Press Release by @AstraZeneca. #LAURA Phase III trial of #Osimertinib vs placebo after chemoradiotherapy for pts with unresectable stage III #EGFRm non-small cell #LungCancer showed POSITIVE results with significant ⬆️ in #PFS. 👇🏼 https://t.co/0BbUP7ALsO https://t.co/W5Y4mezAwc
-
-
Mashup Score: 102Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - 10 month(s) ago
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favourable trend for Tagrisso, although data were not mature
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🚨Hot off the press. Press Release by @AstraZeneca. #LAURA Phase III trial of #Osimertinib vs placebo after chemoradiotherapy for pts with unresectable stage III #EGFRm non-small cell #LungCancer showed POSITIVE results with significant ⬆️ in #PFS. 👇🏼 https://t.co/0BbUP7ALsO https://t.co/W5Y4mezAwc
-
-
Mashup Score: 100Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - 10 month(s) ago
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favourable trend for Tagrisso, although data were not mature
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🚨Hot off the press. Press Release by @AstraZeneca. #LAURA Phase III trial of #Osimertinib vs placebo after chemoradiotherapy for pts with unresectable stage III #EGFRm non-small cell #LungCancer showed POSITIVE results with significant ⬆️ in #PFS. 👇🏼 https://t.co/0BbUP7ALsO https://t.co/W5Y4mezAwc
-
-
Mashup Score: 100Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - 10 month(s) ago
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favourable trend for Tagrisso, although data were not mature
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🚨Hot off the press. Press Release by @AstraZeneca. #LAURA Phase III trial of #Osimertinib vs placebo after chemoradiotherapy for pts with unresectable stage III #EGFRm non-small cell #LungCancer showed POSITIVE results with significant ⬆️ in #PFS. 👇🏼 https://t.co/0BbUP7ALsO https://t.co/W5Y4mezAwc
-
-
Mashup Score: 150FDA approves osimertinib - 10 month(s) ago
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨Hot off the press. The #FDA approves 1st line #Osimertinib WITH chemotherapy for advanced #EGFRm non-small cell #LungCancer. Approval based on #FLAURA2 trial which showed ⬆️#PFS compared to #Osimertinib alone. HR: 0.62 mPFS: 25.5 vs 16.7 months 👇🏼 https://t.co/QRxAgEZgDD https://t.co/FyoOBkvTuP
-
-
Mashup Score: 14Biomarkers in Lung Cancer: Barriers to Implementation | IASLC - 10 month(s) ago
The IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2017 that found one-third of oncologists were unaware of evidence-based gu …
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet-
It was an honor to join the one & only great host/expert Dr. @StephenVLiu & amazing colleagues, Drs @DeboraBrunoMD1 @MattSmeltzer in this special @IASLC “Lung Cancer Considered” #Podcast on: “Biomarkers in #LungCancer.” Tune in👇🏼& Plz take the survey. https://t.co/8BbJfDmHtZ https://t.co/JgODj4vO6g https://t.co/fO0KKB1TRX
-
🔥🚨@OncoAlert HOT OFF THE PRESS @ASCO Living #Guideline Update by great experts @JCO_ASCO on: “Therapy for Stage IV Non-Small-Cell #LungCancer WITH Driver Alterations” #NSCLC #LCSM 👇🏼 https://t.co/rtXKn4200J https://t.co/Ya7dJ4VCwq